Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837208 | 0.84 | ALDH1A1 (0.65) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL25135971 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL11387344 | 0.79 | MAPK1 (0.64) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL24966163 | 0.78 | ALDH1A1 (0.80) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL16903901 | 0.76 | GPBAR1 (0.60) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL15201048 | 0.73 | LMNA (0.45) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL890196 | 0.72 | — | — | |
| SCHEMBL24860332 | 0.70 | ALDH1A1 (0.37) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL15201119 | 0.70 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPK1GABRA1GABRB2 | |
| SCHEMBL15201802 | 0.70 | CYP11B1 (0.44) | ALDH1A1TDP1CYP11B1CYP11B2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1927590-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7858807-B2 | Method for producing 1-substituted-5-acylimidazole compound | UBE INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090306399-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7427626-B2 | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1927590-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20070037839-A1 | useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037839-A1 | useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer | MKI67, CCNI, TYMP | ALDH1A1 130/4885TDP1 219/4885MAPK1 1924/4885 |
| US-20090306399-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | AADAC, KAT5, HDAC5 | ALDH1A1 659/4885TDP1 4262/4885MAPK1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.